welcome
CNBC

CNBC

Health

Health

Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug

CNBC
Summary
Nutrition label

72% Informative

Danish pharmaceutical giant Novo Nordisk said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks .

The company's stock was down 5.4% at 11:22 a.m. London time.